Efficacy of Simparica Trio™, a novel chewable tablet containing sarolaner, moxidectin and pyrantel, against induced hookworm infections in dogs.
Administration, Oral
Ancylostomatoidea
/ growth & development
Animals
Antinematodal Agents
/ administration & dosage
Azetidines
/ administration & dosage
Dog Diseases
/ drug therapy
Dogs
Drug Combinations
Hookworm Infections
/ drug therapy
Life Cycle Stages
/ drug effects
Macrolides
/ administration & dosage
Parasite Load
Pyrantel
/ administration & dosage
Spiro Compounds
/ administration & dosage
Tablets
Treatment Outcome
Ancylostoma caninum
Ancylostomatids
Immature stages
L4 larvae
L5 immature adults
Uncinaria stenocephala
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
01 Mar 2020
01 Mar 2020
Historique:
received:
19
07
2019
accepted:
04
02
2020
entrez:
2
3
2020
pubmed:
3
3
2020
medline:
22
9
2020
Statut:
epublish
Résumé
Ancylostomatids ('hookworms') are among the most important zoonotic nematode parasites infecting dogs worldwide. Ancylostoma caninum and Uncinaria stenocephala are two of the most common hookworm species that infect dogs. Both immature and adult stages of hookworms are voracious blood feeders and can cause death in young dogs before infection can be detected by routine fecal examination. Hence, treatment of both immature and adult stages of hookworms will decrease the risk of important clinical disease in the dog as well as the environmental contamination caused by egg-laying adults, which should reduce the risk of infection for both dogs and humans. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), against induced larval (L Eight negative-controlled, masked, randomized laboratory studies were conducted. Two separate studies were conducted against each of the target parasites and stages. Sixteen or 18 purpose bred dogs, 8 or 9 in each of the two treatment groups, were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Timing of dosing relative to parasite inoculation allowed for efficacy to be evaluated primarily against the target parasite stage. Worm counts were conducted 7 or 8 days after treatments during necropsy. Efficacy was based on the number of worms recovered at necropsy compared to placebo control. Based on geometric mean worm counts, efficacy of Simparica Trio™ was ≥ 98.4% against L These studies confirm the efficacy of a single oral dose of a novel, chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against L
Sections du résumé
BACKGROUND
BACKGROUND
Ancylostomatids ('hookworms') are among the most important zoonotic nematode parasites infecting dogs worldwide. Ancylostoma caninum and Uncinaria stenocephala are two of the most common hookworm species that infect dogs. Both immature and adult stages of hookworms are voracious blood feeders and can cause death in young dogs before infection can be detected by routine fecal examination. Hence, treatment of both immature and adult stages of hookworms will decrease the risk of important clinical disease in the dog as well as the environmental contamination caused by egg-laying adults, which should reduce the risk of infection for both dogs and humans. The studies presented here were conducted to evaluate the efficacy of a novel, oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), against induced larval (L
METHODS
METHODS
Eight negative-controlled, masked, randomized laboratory studies were conducted. Two separate studies were conducted against each of the target parasites and stages. Sixteen or 18 purpose bred dogs, 8 or 9 in each of the two treatment groups, were included in each study. Dogs experimentally infected with the target parasite were dosed once on Day 0 with either placebo tablets or Simparica Trio™ tablets to provide minimum dosages of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5.0 mg/kg pyrantel (as pamoate salt). Timing of dosing relative to parasite inoculation allowed for efficacy to be evaluated primarily against the target parasite stage. Worm counts were conducted 7 or 8 days after treatments during necropsy. Efficacy was based on the number of worms recovered at necropsy compared to placebo control.
RESULTS
RESULTS
Based on geometric mean worm counts, efficacy of Simparica Trio™ was ≥ 98.4% against L
CONCLUSIONS
CONCLUSIONS
These studies confirm the efficacy of a single oral dose of a novel, chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against L
Identifiants
pubmed: 32113471
doi: 10.1186/s13071-020-3951-4
pii: 10.1186/s13071-020-3951-4
pmc: PMC7049382
doi:
Substances chimiques
Antinematodal Agents
0
Azetidines
0
Drug Combinations
0
Macrolides
0
Spiro Compounds
0
Tablets
0
sarolaner
0
Pyrantel
4QIH0N49E7
moxidectin
NGU5H31YO9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99Références
Vet Rec. 2007 Dec 8;161(23):790
pubmed: 18065815
Parasit Vectors. 2020 Mar 1;13(1):72
pubmed: 32113486
Vet Clin North Am Small Anim Pract. 1987 Nov;17(6):1341-54
pubmed: 3328392
Parasitology. 2018 Dec 18;:1-7
pubmed: 30561289
Parasit Vectors. 2020 Mar 1;13(1):71
pubmed: 32113482
Vet Parasitol. 2001 Apr 2;96(3):171-93
pubmed: 11240092
Parasit Vectors. 2020 Mar 1;13(1):100
pubmed: 32113468
Vet Parasitol. 2016 Feb 15;217:29-35
pubmed: 26827857
Trends Parasitol. 2010 Apr;26(4):162-7
pubmed: 20189454
Parasit Vectors. 2012 May 10;5:91
pubmed: 22574783
Parasit Vectors. 2020 Mar 1;13(1):64
pubmed: 32113483
Vet Parasitol. 1994 Apr;52(3-4):179-202
pubmed: 8073602
Vet Ther. 2005 Spring;6(1):15-28
pubmed: 15906267
Am J Vet Res. 1991 Jan;52(1):64-7
pubmed: 2021256
Parasit Vectors. 2019 Sep 11;12(1):445
pubmed: 31506094
Exp Parasitol. 1982 Dec;54(3):303-9
pubmed: 7151941
Parasit Vectors. 2020 Mar 1;13(1):77
pubmed: 32113476
Parasit Vectors. 2020 Mar 1;13(1):57
pubmed: 32113466
Parasit Vectors. 2020 Mar 1;13(1):70
pubmed: 32113470
Vet Parasitol. 2007 Jan 19;143(1):7-13
pubmed: 16971046
Parasit Vectors. 2020 Mar 1;13(1):98
pubmed: 32113472
Vet Parasitol. 2002 Feb 4;103(4):277-97
pubmed: 11777607